Diabetes drug metformin may boost chemo for ovarian cancer

NCT ID NCT02122185

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase II trial tested whether adding metformin, a common diabetes drug, to standard chemotherapy could help control advanced ovarian, fallopian tube, or primary peritoneal cancer. 111 participants received either metformin or a placebo alongside chemotherapy, followed by maintenance therapy. The goal was to see if metformin could delay cancer progression by making tumor cells more sensitive to chemo.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

metformin hydrochloride (Glucophage)

What this could lead to

If successful, this could point toward a way to make chemotherapy more effective for advanced ovarian cancer, potentially delaying disease progression.

What could go wrong

This is a phase II trial with only 111 participants, so results are preliminary. Metformin may not improve outcomes, and side effects from chemotherapy remain a risk.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OVARIAN ENDOMETRIOID ADENOCARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Brenner tumor Carcinoma, Ovarian Epithelial fallopian tube cancer fallopian tube carcinoma fallopian tube neoplasm malignant germ cell tumor of ovary ovarian carcinoma ovarian clear cell cystadenocarcinoma ovarian endometrioid adenocarcinoma ovarian germ cell tumor ovarian seromucinous carcinoma ovarian serous cystadenocarcinoma peritoneum cancer Pleural Effusion, Malignant primary peritoneal carcinoma undifferentiated ovarian carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • City of Hope

    Duarte, California, 91010, United States

  • Decatur Memorial Hospital

    Decatur, Illinois, 62526, United States

  • Ingalls Memorial Hospital

    Harvey, Illinois, 60426, United States

  • Mayo Clinic

    Rochester, Minnesota, 55905, United States

  • Mitchell Cancer Institute - University of South Alabama

    Mobile, Alabama, 36604, United States

  • NCH Medical Group- Northwest Community Hospital

    Arlington Heights, Illinois, 60005, United States

  • NorthShore University HealthSystem

    Evanston, Illinois, 60201, United States

  • Rush University Medical Center

    Chicago, Illinois, 60612, United States

  • University of Alabama

    Birmingham, Alabama, 35233, United States

  • University of Chicago

    Chicago, Illinois, 60637, United States